← All trials
NCT06694753
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 19, 2025
- Primary completion
- Dec 19, 2025
- Completion date
- Dec 19, 2025
- First posted
- Nov 19, 2024
- Last posted
- Nov 19, 2024
- Enrollment
- 96
- Arms / groups
- 8 / —
- Source
- AACT · ctgov ingestion
Sponsors
- International AIDS Vaccine InitiativeLead sponsor
- HIV Vaccine Trials NetworkLead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- Perinatal HIV Research Unit, BaragwanathOfficial
- National Institutes of Health (NIH)Collaborator
- ScrippsCollaborator
- United States Agency for International DevelopmentCollaborator
- Moderna TherapeuticsCollaborator
- Bill and Melinda Gates FoundationCollaborator
- International AIDS Vaccine InitiativeCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.